Showing 1721-1730 of 2058 results for "".
- Clearside Biomedical Completes Randomization in Phase 2b Clinical Trial of CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-randomization-in-phase-2b-clinical-trial-of-cls-ax-in-wet-amd/2482013/Clearside Biomedical announced it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in wet age-related macular degeneration (AMD). Topline data results are expected in the third quarter of 2024. “As we continue
- Tarsus Announces Topline Phase 2a Trial Results Evaluating TP-03 for the Treatment of MGD in Patients with Demodex Miteshttps://modernod.com/news/tarsus-announces-topline-phase-2a-trial-results-evaluating-tp-03-for-the-treatment-of-mgd-in-patients-with-demodex-mites/2482004/Tarsus Pharmaceuticals announced topline results from the Ersa phase 2a clinical trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) administered twice daily (BID) or three times a day (TID) for 12 weeks for the treatment of meibomian gland disease (MGD) in patients with Demodex&nb
- Regenxbio Presents New Data on Investigational AAV Therapeutic for Retinal Conditionshttps://modernod.com/news/regenxbio-presents-new-data-on-investigational-aav-therapeutic-at-aao/2481967/At the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco, new data was presented for Regenxbio's ABBV-RGX-314, an investigational one-time AAV therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degener
- Pixium Vision Announces the Launch of a Process to Find Buyershttps://modernod.com/news/pixium-vision-announces-the-launch-of-a-process-to-find-buyers/2481900/Pixium Vision SA announced that a tender process (appel d’offres) for the purpose of finding buyers to acquire the company's business will be published October 19. Unable to find financial investors within the restricted timeframe and in line with the company's n
- Tilak Healthcare Raises €10 Million to Continue Growing Its Ophthalmological Telemedicine Offeringhttps://modernod.com/news/tilak-healthcare-raises-eur10-million-to-continue-growing-its-leading-ophthalmological-telemedicine-offering/2481890/Tilak Healthcare has raised €10 million in a funding to accelerate the roll-out of OdySight in France and abroad, and to develop new solutions for other medical conditions. OdySight is the first remote monitoring system for ophthalmic conditions combined with a gaming interface designed
- Sight Sciences Presents Phase 1 Results of the SAHARA Trial Comparing TearCare to Restasis for the Treatment of Dry Eye Diseasehttps://modernod.com/news/sight-sciences-presents-phase-1-results-of-the-sahara-trial-comparing-tearcare-to-restasis-for-the-treatment-of-dry-eye-disease/2481888/Sight Sciences announced the presentation of the full phase 1 results from the SAHARA randomized controlled trial, demonstrating that interventional eyelid procedures for dry eye disease enabled by TearCare technology were superior at all measured time points to Restasis prescription eye dro
- BioTissue Presents New Data for Cryopreserved Amniotic Membrane Therapyhttps://modernod.com/news/biotissue-presents-new-data-for-cryopreserved-amniotic-membrane-therapy/2481880/Findings of a new multicenter, retrospective study conducted on patients with moderate to severe dry eye disease (DED) treated with BioTissue’s self-retained Prokera Slim Amniotic Membrane corneal bandage show significantly improved patient outcomes in less time, according to
- Melt Pharmaceuticals Announces Development and License Agreement with Catalent for Its Zydis Fast-Dissolve Technologyhttps://modernod.com/news/melt-pharmaceuticals-announces-development-and-license-agreement-with-catalent-for-its-zydis-fast-dissolve-technology/2481857/Melt Pharmaceuticals, a former subsidiary of Harrow Health, announced it has entered into an exclusive development and license agreement with Catalent in which Melt will utilize Catalent’s proprietary Zydis orally disintegrating tablet (ODT) fast-dissolve technology with MELT
- DigitalOptometrics to Demonstrate Its Remote Comprehensive Exam Services With Instant Language Translation Capabilities at Vision Expo Westhttps://modernod.com/news/digitaloptometrics-to-demonstrate-its-remote-comprehensive-exam-services-with-instant-language-translation-capabilities-at-vision-expo-west/2481811/DigitalOptometrics, a provider of remote comprehensive eye exam services, will demonstrate its technology at Vision Expo West, September 28-30. Attendees can interact with a remote optometrist in real-time and experience a patient-centric comprehensive eye exam conducted via high-definition
- Skyline Therapeutics’ Gene Therapy Candidate for Wet AMD Receives IND Clearancehttps://modernod.com/news/skyline-therapeutics-gene-therapy-candidate-for-namd-receives-ind-clearance/2481758/Skyline Therapeutics announced that the FDA has cleared the company’s investigational new drug (IND) application for a phase 1/2a clinical trial of SKG0106, a one-time intravitreally delivered adeno-associated virus (AAV) gene therapy for the treatment of wet age-related macular degene